Top 5 Target	Count

CD28 x VISTA	2
VISTA(V-domain Ig suppressor of T-cell activation)	2
CD39(Ectonucleoside triphosphate diphosphohydrolase 1)	1
PD-1(Programmed cell death protein 1)	1
VSIG4(V-set and immunoglobulin domain-containing protein 4)	1

Drugs associated with Sensei Biotherapeutics, Inc.

Cemiplimab-RWLC

Target

PD-1

Mechanism

PD-1 inhibitors

Active Org.

Sanofi (China) Investment Co. Ltd. [+16]

Originator Org.

Regeneron Pharmaceuticals, Inc.

Active Indication

Metastatic Carcinoma to the Uterine Cervix [+77]

Inactive Indication

Advanced biliary tract cancer [+17]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date28 Sep 2018

SNS-101(Sensei Biotherapeutics)

Target

VISTA

Mechanism

VISTA inhibitors

Active Org.

Sensei Biotherapeutics, Inc.

Originator Org.

Sensei Biotherapeutics, Inc.

Active Indication

Advanced cancer [+16]

Inactive Indication-

Drug Highest PhasePhase 1/2

First Approval Ctry. / Loc.-

First Approval Date-

SNS 401 NG

Target-

Mechanism

Immunostimulants

Active Org.

University of Washington

Originator Org.

Sensei Biotherapeutics, Inc.

Active Indication

Merkel Cell Carcinoma

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Sensei Biotherapeutics, Inc.

NCT05864144 / RecruitingPhase 1/2

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.

Start Date31 May 2023

Sponsor / Collaborator

Sensei Biotherapeutics, Inc.

[+1]

NCT04217720 / WithdrawnPhase 2

An Open-Label, Multi-Center Phase 2 Clinical Trial Evaluating SNS-301 in Patients With ASPH+ High Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

To evaluate safety, immunogenicity and anti-tumor responses of intradermally delivered SNS-301 in patients with ASPH+ high risk MDS and CMML.

Start Date01 Apr 2020

Sponsor / Collaborator

Sensei Biotherapeutics, Inc.

NCT04034225 / TerminatedPhase 1/2

An Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic/Recurrent Squamous Cell Carcinoma of the Head and Neck

To evaluate safety, immunogenicity and anti-tumor responses of intradermally delivered SNS-301 added to checkpoint inhibitor therapy in locally advanced unresectable or metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN) patients.

Start Date11 Nov 2019

Sponsor / Collaborator

Sensei Biotherapeutics, Inc.

100 Clinical Results associated with Sensei Biotherapeutics, Inc.

0 Patents (Medical) associated with Sensei Biotherapeutics, Inc.

Literatures (Medical) associated with Sensei Biotherapeutics, Inc.

01 Dec 2023·JAMA Oncology

Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma

Article

Author: O'Malley, Ryan B ; Smythe, Kimberly ; Yu, Yuexin ; Berglund, Peter ; Lu, Hailing ; Black, Graeme ; Hermida de Viveiros, Pedro ; Pierce, Robert H ; Hsu, Cynthia ; Pillarisetty, Venu G ; Kim, Edward Y ; Bonham, Lynn ; Cranmer, Lee D ; Riddell, Stanley R ; Kane, Gabrielle ; Ter Meulen, Jan ; Hsu, Frank J ; Seo, Yongwoo David ; Wagner, Michael J ; Loggers, Elizabeth T ; Ng, Juliana ; Schroeder, Brett A ; Jones, Robin L ; Alexiev, Borislav A ; Pollack, Seth M ; Mi, Xinlei ; Warren, E Houston

ImportanceMetastatic soft tissue sarcomas (STSs) have limited systemic therapy options, and immunomodulation has not yet meaningfully improved outcomes. Intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist glycopyranosyl lipid A in stable-emulsion formulation (GLA-SE) has been studied as immunotherapy in other contexts.ObjectiveTo evaluate the safety, efficacy, and immunomodulatory effects of IT GLA-SE with concurrent radiotherapy in patients with metastatic STS with injectable lesions.Design, Setting, and ParticipantsThis phase 1 nonrandomized controlled trial of patients with STS was performed at a single academic sarcoma specialty center from November 17, 2014, to March 16, 2016. Data analysis was performed from August 2016 to September 2022.InterventionsTwo doses of IT GLA-SE (5 μg and 10 μg for 8 weekly doses) were tested for safety in combination with concurrent radiotherapy of the injected lesion.Main Outcomes and MeasuresPrimary end points were safety and tolerability. Secondary and exploratory end points included local response rates as well as measurement of antitumor immunity with immunohistochemistry and T-cell receptor (TCR) sequencing of tumor-infiltrating and circulating lymphocytes.ResultsTwelve patients (median [range] age, 65 [34-78] years; 8 [67%] female) were treated across the 2 dose cohorts. Intratumoral GLA-SE was well tolerated, with only 1 patient (8%) experiencing a grade 2 adverse event. All patients achieved local control of the injected lesion after 8 doses, with 1 patient having complete regression (mean regression, −25%; range, −100% to 4%). In patients with durable local response, there were detectable increases in tumor-infiltrating lymphocytes. In 1 patient (target lesion −39% at 259 days of follow-up), TCR sequencing revealed expansion of preexisting and de novo clonotypes, with convergence of numerous rearrangements coding for the same binding sequence (suggestive of clonal convergence to antitumor targets). Single-cell sequencing identified these same expanded TCR clones in peripheral blood after treatment; these T cells had markedly enhanced Tbet expression, suggesting TH1 phenotype.Conclusions and RelevanceIn this nonrandomized controlled trial, IT GLA-SE with concurrent radiotherapy was well tolerated and provided more durable local control than radiotherapy alone. Patients with durable local response demonstrated enhanced IT T-cell clonal expansion, with matched expansion of these clonotypes in the circulation. Additional studies evaluating synergism of IT GLA-SE and radiotherapy with systemic immune modulation are warranted.Trial RegistrationClinicalTrials.gov Identifier: NCT02180698

30 Aug 2023·Antibodies (Basel, Switzerland)

Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics.

Review

Author: Thisted, Thomas ; Smith, F Donelson ; van der Horst, Edward H ; Pierce, Robert H

Immune checkpoints and other immunoregulatory targets can be difficult to precisely target due to expression on non-tumor immune cells critical to maintaining immune homeostasis in healthy tissues. On-target/off-tumor binding of therapeutics results in significant pharmacokinetic and pharmacodynamic problems. Target-mediated drug disposition (TMDD) significantly limits effective intratumoral drug levels and adversely affects anti-tumor efficacy. Target engagement outside the tumor environment may lead to severe immune-related adverse events (irAEs), resulting in a narrowing of the therapeutic window, sub-optimal dosing, or cessation of drug development altogether. Overcoming these challenges has become tractable through recent advances in antibody engineering and screening approaches. Here, we review the discovery and development of conditionally active antibodies with minimal binding to target at physiologic pH but high-affinity target binding at the low pH of the tumor microenvironment by focusing on the discovery and improved properties of pH-dependent mAbs targeting two T cell checkpoints, VISTA and CTLA-4.

14 Apr 2022·Clinical Cancer ResearchQ1 · MEDICINE

Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells

Q1 · MEDICINE

Article

Author: Murphy, Erin ; Flanagan, Kevin C. ; Pierce, Robert H. ; Spraker, Matthew B. ; LaFranzo, Natalie A. ; McClanahan, Terrill K. ; Jones, Robin L. ; Thompson, Matthew J. ; Riolobos, Laura ; Mantilla, Jose G. ; Ricciotti, Robert ; Cranmer, Lee D. ; Seo, Y. David ; Smythe, Kimberly S. ; Blumenschein, Wendy M. ; Kane, Gabrielle M. ; LaFleur, Bonnie J. ; Kim, Edward Y. ; Pollack, Seth M. ; Wagner, Michael J. ; Campbell, Jean S. ; Schaub, Stephanie K. ; Earls, Jon ; Kim, Teresa S. ; Zhang, Yuzheng ; Loggers, Elizabeth T. ; He, Qianchuan ; Chen, Eleanor Y. ; Goff, Peter H.

AbstractPurpose:To characterize changes in the soft-tissue sarcoma (STS) tumor immune microenvironment induced by standard neoadjuvant therapy with the goal of informing neoadjuvant immunotherapy trial design.Experimental Design:Paired pre- and postneoadjuvant therapy specimens were retrospectively identified for 32 patients with STSs and analyzed by three modalities: multiplexed IHC, NanoString, and RNA sequencing with ImmunoPrism analysis.Results:All 32 patients, representing a variety of STS histologic subtypes, received neoadjuvant radiotherapy and 21 (66%) received chemotherapy prior to radiotherapy. The most prevalent immune cells in the tumor before neoadjuvant therapy were myeloid cells (45% of all immune cells) and B cells (37%), with T (13%) and natural killer (NK) cells (5%) also present. Neoadjuvant therapy significantly increased the total immune cells infiltrating the tumors across all histologic subtypes for patients receiving neoadjuvant radiotherapy with or without chemotherapy. An increase in the percentage of monocytes and macrophages, particularly M2 macrophages, B cells, and CD4+ T cells was observed postneoadjuvant therapy. Upregulation of genes and cytokines associated with antigen presentation was also observed, and a favorable pathologic response (≥90% necrosis postneoadjuvant therapy) was associated with an increase in monocytic infiltrate. Upregulation of the T-cell checkpoint TIM3 and downregulation of OX40 were observed posttreatment.Conclusions:Standard neoadjuvant therapy induces both immunostimulatory and immunosuppressive effects within a complex sarcoma microenvironment dominated by myeloid and B cells. This work informs ongoing efforts to incorporate immune checkpoint inhibitors and novel immunotherapies into the neoadjuvant setting for STSs.

News (Medical) associated with Sensei Biotherapeutics, Inc.

29 Oct 2024

·www.globenewswire.com

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the Company will present at two upcoming scientific conferences. Conference and Presentation Details: PEGS Europe: Protein and Antibody Engineering Summit, November 5-7, 2024, Barcelona, Spain Title: Selectively Targeting VISTA in the Tumor-Microenvironment with SNS-101, a Conditionally Active Monoclonal Antibody Presenter: Edward van der Horst, Ph.D., Chief Scientific Officer Session: Antibody-Based Cancer TherapiesDate and time: Tuesday, November 5, 2024, 9:00 a.m. CET (Central European Time) Society for Immunotherapy Cancer (SITC) 39th Annual Meeting, November 6-10, Houston Texas Title: Spatial proteomic profiling of VISTA and PSGL-1 interactions across cancer indicationsPresenter: F. Donelson Smith, Ph.D., Senior Director, Biologics Discovery & Early DevelopmentPresentation Type: PosterAbstract Number: 70Date and Time: Saturday, November 9, 2024, 12:15–1:45 p.m. & 7:00-8:30 p.m. CST. Location: Level 1-Exhibit Halls AB (George R. Brown Convention Center) About Sensei Biotherapeutics Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn. Investor Contact:Michael BiegaSenior Director, Investor RelationsSensei Biotherapeuticsmbiega@senseibio.com Media Contact:Joyce AllaireLifeSci AdvisorsJallaire@lifesciadvisors.com

Immunotherapy

26 Sep 2024

·www.businesswire.com

Immuno-Oncology Therapeutics Forecasts to 2027: The Race for the Cures - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer including Executive and Consultant Guides. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. CAR-T Cells? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Already worth billions the global market is poised for dramatic growth. The impact on the health care industry is enormous. The report forecasts the market size out to 2027. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size. Make investment decisions and valuations with confidence using the latest data. This report explores the opportunity in this market and what companies are poised to benefit. Key Topics Covered: 1 Market Guides 1.1 Situation Analysis 1.2 Guide for Executives and Marketing Staff 1.3 Guide for Investment Analysts and Management Consultants 2 Introduction and Market Definition 2.1 What is Cancer Immunotherapy? 2.2 Immunotherapy - the looming cures 2.3 Market Definition 2.4 Methodology 2.5 U.S. Medical Market and Pharmaceutical Spending - Perspective 2.5.1 Global Expenditures for Medicines 3 Immunotherapy - Guide to Immune Technologies 3.1 The Immune System 3.1.1 Innate immune system 3.1.2 Adaptive immune system 3.1.3 Tumor immunology - the immune surveillance system 3.2 Immuno Oncology Technologies 3.2.1 Monoclonal Antibodies 3.2.2 Cancer vaccines 3.2.3 Cytokines 3.2.4 Cell Based Therapies 3.2.5 Inhibitors/Agonists 3.2.6 Antibody Drug Conjugates 3.2.7 Others 4 Industry Overview 4.1 Market Players - Roles & Impacts 4.1.1 Drug manufacturers - Larger/pharmaceutical 4.1.2 Drug manufacturers - Generic 4.1.3 Contract Research and Manufacturing 4.1.4 In Vitro Diagnostics Industry 4.1.5 Drug Marketing Companies 4.1.6 Biotechnology Companies 4.1.7 Regulatory Bodies 5 Market Trends 5.1 Factors Driving Growth 5.1.1 Outcome potential 5.1.2 Fast tracking 5.1.3 Funding 5.1.4 Technology Environment 5.1.5 Target Solutions 5.2 Factors Limiting Growth 5.2.1 Cost of Treatment 5.2.2 Clinical Trials Role 5.2.3 Combinations 5.2.4 Protocols 5.3 Therapeutic Technology Development 5.3.1 Combinations - Issues and Complexity 5.3.2 Preference for a drug 5.3.3 Problems of Immunity Engineering 5.3.4 The Role of Cost 5.3.5 The Disruption Dynamic 5.3.6 CAR-T Cell Therapy 5.3.7 The Next Five Years 6 Cancer Immunotherapy Recent Developments 6.1 Recent Developments - Importance and How to Use This Section 6.2 Continued Success with Immunotherapy in Melanoma 6.3 AC Immune Receives FDA Fast Track Designation 6.4 LTZ Announces Financing 6.5 Immunotherapy for Cancer Overview 6.6 Implantable device shrinks pancreatic tumors 6.7 mRNA Vaccine And Immunotherapy Reduce Melanoma Recurrence 6.8 Towards a Universal Cancer Immunotherapy 6.9 New Strategy May Improve T-Cell Therapy in Solid Tumors 6.10 Immunotherapy linked to increase in Medicare spending 6.11 Immunotherapy Effective with Ovarian Cancer 6.12 Cancer Immunotherapy Granted Fast Track 7 Profiles of Key Immunotherapy Companies AbbVie Achilles Therapeutics Acumen Pharmaceuticals Adagene Adaptimmune Therapeutics Adicet Bio ALX Oncology Holdings Ambrx Biopharma Amgen Apexigen Arcus Biosciences argenx AstraZeneca Atreca Avalo Therapeutics Avid Bioservices Bavarian Nordic BioAtla Biogen Inc. BioNTech Bolt Biotherapeutics Bristol-Myers Squibb Candel Therapeutics Caribou Biosciences Celldex Therapeutics Checkpoint Therapeutics Chinook Therapeutics Corvus Pharmaceuticals Cullinan Oncology Eli Lilly EOM Pharmaceuticals Evaxion Biotech Genenta Science Gilead Sciences Gracell Biotechnologies Greenwich LifeSciences Gritstone bio Harpoon Therapeutics ImmunityBio Immunocore Holdings Immunome IMV Inc Incyte Indaptus Therapeutics Instil Bio Iovance Biotherapeutics Johnson & Johnson Marker Therapeutics Medicenna Therapeutics Merck & Co. Merus Moderna Mustang Bio Nanobiotix Neoleukin Therapeutics Novartis Novavax Oncorus PDS Biotechnology Pfizer Regeneron Pharmaceuticals Roche Sanofi Sensei Biotherapeutics Senti Biosciences Surface Oncology Takeda Pharmaceutical TC Biopharm ThermoGenesis Holdings UroGen Pharma Werewolf Therapeutics Xilio Therapeutics Zymeworks 8 The Global Market for Immuno-Oncology Therapeutics 8.1 Global Market Overview by Country 8.2 Global Market by Therapy 8.3 Global Market by Cancer 8.4 Global Market by Customer 9 Global Immuno-Oncology Therapy Markets - By Therapy 9.1 MAB 9.2 Cytokine 9.3 Vaccine 9.4 Cell Based 9.5 Inhibitor/Agonist 9.6 Other IO Therapy 10 Global Immuno-Oncology Therapeutic Markets - By Cancer 10.1 Breast 10.2 ColoRectal 10.3 Cervical 10.4 Lung 10.5 Precancer 10.6 Prostate 10.7 Melanoma 10.8 Blood 10.9 Other Cancer 11 Global Immuno-Oncology Therapeutic Markets - By Customer 11.1 Pharma 11.2 Clinic 11.3 Other Customer For more information about this report visit https://www.researchandmarkets.com/r/8355qg About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ImmunotherapyFast TrackASCO

04 Sep 2024

·www.biospace.com

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that preclinical data on SNS-103 will be presented in a poster session at the CRI-ENCI Eighth International Immunotherapy Conference, being held September 8-11, 2024, at the Gaylord National Resort & Convention Center in National Harbor, MD. Presentation Details: CRI-ENCI Eighth International Cancer Immunotherapy Conference Title: Pre-clinical characterization of monoclonal antibodies targeting CD39 activity in the acidic tumor microenvironment Presenter: F. Donelson Smith, Ph.D., Senior Director, Biologics Discovery & Early Development Poster Number: 195A Date and time: Sunday, September 8, 2024, 12:05 – 2:05 p.m. EDT About Sensei Biotherapeutics  Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm. For more information, please visit  , and follow the company on X @SenseiBio and  LinkedIn . Investor Contact: Michael Biega Senior Director, Investor Relations Sensei Biotherapeutics mbiega@senseibio.com Media Contact: Joyce Allaire LifeSci Advisors Jallaire@lifesciadvisors.com

ImmunotherapyAACR

100 Deals associated with Sensei Biotherapeutics, Inc.

100 Translational Medicine associated with Sensei Biotherapeutics, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 27 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Phase 2 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

SNS-101(Sensei Biotherapeutics) ( VISTA )	Stomach Cancer More	Phase 2 Clinical
Cemiplimab-RWLC ( PD-1 )	Breast Cancer More	Phase 2 Clinical
SNS-103 ( CD39 )	Solid tumor More	Preclinical
PH Selective Anti-CD28/VISTA Bispecific Antibody ( CD28 x VISTA )	Neoplasms More	Preclinical
SNS-201 ( CD28 x VISTA )	Solid tumor More	Discovery

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis